PPA
TVTX icon

Parametric Portfolio Associates’s Travere Therapeutics TVTX Stock Holding History

Parametric Portfolio Associates’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$2.54M Sell
98,367
-10,727
-10% -$285K ﹤0.01% 2298
2021
Q4 		$3.39M Buy
109,094
+30,004
+38% +$845K ﹤0.01% 2120
2021
Q3 		$1.92M Buy
79,090
+6,799
+9% +$125K ﹤0.01% 2463
2021
Q2 		$1.05M Sell
72,291
-113,104
-61% -$2.23M ﹤0.01% 2744
2021
Q1 		$4.63M Sell
185,395
-16,938
-8% -$468K ﹤0.01% 2230
2020
Q4 		$5.51M Buy
202,333
+21,309
+12% +$497K ﹤0.01% 2008
2020
Q3 		$3.34M Sell
181,024
-10,825
-6% -$210K ﹤0.01% 2164
2020
Q2 		$3.92M Buy
191,849
+136,976
+250% +$2.18M ﹤0.01% 2051
2020
Q1 		$801K Sell
54,873
-8,526
-13% -$128K ﹤0.01% 2920
2019
Q4 		$900K Buy
63,399
+51,132
+417% +$653K ﹤0.01% 3109
2019
Q3 		$142K Sell
12,267
-9,947
-45% -$164K ﹤0.01% 3773
2019
Q2 		$446K Sell
22,214
-71,231
-76% -$1.41M ﹤0.01% 3407
2019
Q1 		$2.12M Sell
93,445
-6,900
-7% -$152K ﹤0.01% 2624
2018
Q4 		$2.27M Sell
100,345
-1,813
-2% -$45.1K ﹤0.01% 2497
2018
Q3 		$2.94M Buy
102,158
+12,981
+15% +$371K ﹤0.01% 2430
2018
Q2 		$2.43M Buy
89,177
+53,775
+152% +$1.43M ﹤0.01% 2550
2018
Q1 		$792K Buy
35,402
+2,015
+6% +$48K ﹤0.01% 3128
2017
Q4 		$703K Sell
33,387
-2,611
-7% -$59.7K ﹤0.01% 3172
2017
Q3 		$896K Buy
35,998
+2,535
+8% +$55.8K ﹤0.01% 3099
2017
Q2 		$649K Buy
33,463
+1,192
+4% +$21.6K ﹤0.01% 3216
2017
Q1 		$596K Sell
32,271
-1,691
-5% -$33.1K ﹤0.01% 3113
2016
Q4 		$643K Buy
+33,962
New +$695K ﹤0.01% 3060
2016
Q1 		– Sell
-10,764
Closed -$208K – 4026
2015
Q4 		$208K Buy
+10,764
New +$215K ﹤0.01% 3720
2015
Q3 		– Sell
-10,011
Closed -$332K – 3329
2015
Q2 		$332K Buy
+10,011
New +$274K ﹤0.01% 3513
2014
Q4 		– Sell
-14,076
Closed -$127K – 4002
2014
Q3 		$127K Buy
+14,076
New +$166K ﹤0.01% 3689

Other funds holding TVTX

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Parametric Portfolio Associates's TVTX Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its Travere Therapeutics (TVTX) stake by 9.8% in Q1 2022, selling an estimated $285K and leaving 98,367 shares worth $2.54M. The position accounts for ﹤0.01% of the portfolio, ranked #2298.

Parametric Portfolio Associates first reported a position in TVTX in Q3 2014 and has held it in 25 quarters since. The position peaked at $5.51M in Q4 2020. 169 funds tracked by Wall St. Rank hold TVTX as of Q1 2022.

  • Parametric Portfolio Associates held 98,367 shares of Travere Therapeutics worth $2.54M as of Q1 2022.
  • Parametric Portfolio Associates sold 10,727 Travere Therapeutics shares in Q1 2022, an estimated $285K.
  • Travere Therapeutics made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #2298 holding.
  • Parametric Portfolio Associates first reported a position in Travere Therapeutics in Q3 2014 and has held it in 25 quarters since.
  • Parametric Portfolio Associates's Travere Therapeutics position peaked at $5.51M in Q4 2020.
  • 169 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.